Top Markets
#1 Zora Zora +33.25%
#2 Axelar Axelar +22.71%
#3 Seeker Seeker +22.17%
#4 AI XOVIA AI XOVIA +20.93%
#5 Full Moon Full Moon +18.72%
#6 0G 0G +14.77%
#7 Notcoin Notcoin +12.78%
#8 rsERG rsERG +10.58%
#9 VVS Finance VVS Finance +10.36%
#10 Cryptopia Cryptopia +10.26%
Coin of the day
Zora Zora
Settings
Language
ENGLISH
Currency
USD
Theme
Jinling Pharmaceutical Company Limited Jinling Pharmaceutical Company Limited

Jinling Pharmaceutical Company Limited

000919
Rank in Stocks #12244
Jinling Pharmaceutical Company Limited is a Chinese enterprise specializing in... Jinling Pharmaceutical Company Limited is a Chinese enterprise specializing in the manufacture and distribution of a diverse range of pharmaceutical products. Its key offerings include the Mailuoning injection, prescribed for the management of numerous vascular and thrombotic conditions such as thrombo-occlusive vasculitis, arteriosclerotic occlusive disease, cerebral thrombosis and its sequelae, multiple forms of arteritis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, and thrombophlebitis. The company also provides ferrous succinate tablets for the prevention and treatment of iron deficiency anemia, alongside lentinan injection used in the therapy of malignant tumors. Furthermore, Jinling Pharmaceutical offers medical health care services. The firm's operations are primarily based in Nanjing, China.
Share Price
$0.97092303
Market Cap
$603.84M
Change (1 day)
-2.19%
Change (1 year)
-2.62%
Country
CN
Trade Jinling Pharmaceutical Company Limited (000919)

Category

Healthcare
Revenue for Jinling Pharmaceutical Company Limited (000919)
Revenue in Aug 2026 TTM: 0
According to Jinling Pharmaceutical Company Limited latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Jinling Pharmaceutical Company Limited from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited
1177.HK
 $4.55B -
HK